Analysts Positive On Keryx Biopharmaceuticals, Inc. Despite Weak Prescription Data
May 05, 2015 at 12:24 PM EDT
Keryx posted total revenue of $1.175 million, including 1,218 prescriptions filled for Auryxia in the quarter.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.